Merck Sharp + Dohme Corp.

Itzia Arroyo

Tesfaye Biftu

Yanfeng Zhang

Ping Chen

Faye Sheen

Aaron J Moment

Davida Krueger

Benjamin Cohen

Aaron S Cote

Alfred Lee

Michael J McNevin

Jason T Ash

Christopher Wahl

Binfeng Xia

The present invention relates to novel Inclusion Complexes of Compound A, compositions comprising an Inclusion Complex of Compound A, and methods of using the Inclusion Complexes of Compound A for preparing compositions useful for treating or preventing HCV infection in a patient, wherein Compound A has the structure: 

Inclusion complexes of an HCV NS5B inhibitor and uses thereof

Novel crystalline forms of (2R,3S,5R)-2-(2,5-Difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine are potent inhibitors of dipeptidyl peptidase-IV and are useful for the treatment of non-insulin dependent (Type 2) diabetes mellitus. The invention also relates to pharmaceutical compositions containing these novel forms, processes to prepare these forms and their pharmaceutical compositions as well as uses thereof for the treatment of Type 2 diabetes.

Crystalline forms of a dipeptidyl peptidase-IV inhibitors

Crystalline forms of a dipeptidyl peptidase-IV inhibitor

A thermodynamically controlled process for preparing Form I polymorph of lamivudine is described, wherein the process involves crystallizing Form I at a temperature of from about 0&#xb0; C. to about 50&#xb0; C. from a mixture which comprises (a) lamivudine or an acid salt thereof or both, (b) a solvent system comprising water and at least one organic solvent, and optionally (c) Form I seed; wherein, when a lamivudine acid salt is employed in the mixture, the crystallizing step is conducted in the presence of a base; and wherein the water activity of the solvent system is maintained in a range in which Form I is thermodynamically the most stable form of lamivudine.

Preparation of lamivudine form I

Growing community of inventors

Union, NJ, United States of America

Itzia Arroyo